Top Page
HBM Holdings Ltd.
(2142)
HBM Holdings Ltd. (2142) vs. iShares MSCI Hong Kong ETF (EWH)
HBM Holdings Ltd. Business Overview & Revenue Model
HBM Holdings Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.10M | 89.50M | 40.66M | 4.31M | 14.11M |
| Gross Profit | 33.61M | 87.47M | 40.53M | 4.17M | 13.66M |
| EBITDA | -896.00K | 31.18M | -115.50M | -130.84M | -290.91M |
| Net Income | 2.78M | 22.80M | -137.27M | -137.88M | -296.54M |
Balance Sheet | |||||
| Total Assets | 215.01M | 228.48M | 232.12M | 282.36M | 388.74M |
| Cash, Cash Equivalents and Short-Term Investments | 167.22M | 140.72M | 171.71M | 216.30M | 356.95M |
| Total Debt | 61.34M | 66.01M | 90.93M | 19.47M | 1.73M |
| Total Liabilities | 90.96M | 108.85M | 139.62M | 59.45M | 27.73M |
| Stockholders Equity | 124.45M | 119.99M | 92.83M | 223.19M | 361.19M |
Cash Flow | |||||
| Free Cash Flow | 30.44M | -21.60M | -118.40M | -139.81M | -35.99M |
| Operating Cash Flow | 30.68M | -19.12M | -99.96M | -125.61M | -35.39M |
| Investing Cash Flow | 6.55M | 28.09M | 137.59M | -76.90M | -93.53M |
| Financing Cash Flow | -10.24M | -29.14M | 70.58M | 1.59M | 357.86M |
HBM Holdings Ltd. Technical Analysis
HBM Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | HK$11.44B | 60.09 | 6.73% | ― | 23.37% | ― | |
61 Neutral | HK$10.52B | 57.57 | 9.52% | ― | 185.36% | ― | |
60 Neutral | HK$19.40B | 4.63 | -1.43% | 3.30% | 11.28% | -16.47% | |
57 Neutral | HK$18.92B | ― | -21.42% | ― | 240.05% | -140.09% | |
54 Neutral | HK$10.41B | 428.97 | 2.28% | ― | -57.55% | -87.49% | |
49 Neutral | HK$13.90B | ― | -95.84% | ― | -55.64% | -158.67% | |
| ― | HK$10.02B | 104.21 | 4.95% | ― | ― | ― |
HBM Holdings Ltd. Corporate Events
HBM Holdings Limited, a company incorporated in the Cayman Islands, has announced that its Board of Directors will meet on August 27, 2025, to consider and approve the interim results for the first half of 2025. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, potentially impacting stakeholders’ perceptions and the company’s market positioning.
HBM Holdings Ltd. announced that it will present Phase II clinical data for its anti-CTLA-4 antibody, porustobart (HBM4003), in combination with tislelizumab, at the ESMO Congress 2025. This presentation will highlight the efficacy and safety of the treatment for microsatellite stable metastatic colorectal cancer, potentially enhancing the company’s position in the oncology market.
HBM Holdings Ltd. has issued a positive profit alert, anticipating a significant profit increase for the first half of 2025, ranging between approximately US$68 million to US$74 million. This growth is primarily driven by strategic collaborations, including a partnership with AstraZeneca, and successful out-licensing and business development activities that have contributed to a stable revenue stream.
HBM Holdings Ltd. announced that its investee company, Shanghai NK Cell Technology Co., LTD, has successfully completed an A+++ round of financing, raising nearly RMB100 million. This funding will be used to advance clinical trials and support the development of NK Cell-Tech’s product pipeline, reflecting strong investor confidence in its innovative immunotherapy platform.
HBM Holdings Limited, a company incorporated in the Cayman Islands, has announced the grant of 3,465,000 share options to three non-connected employees under its Share Option Scheme. The options, granted on June 30, 2025, are set at an exercise price of HK$8.604 per share and will vest over a period of four years, subject to performance appraisals. This initiative aims to incentivize employees and align their interests with the company’s long-term goals, potentially enhancing employee retention and performance.
HBM Holdings Limited has outlined the terms of reference for its Nomination Committee, which was established by the board of directors in August 2020. The committee’s primary responsibilities include identifying and recommending candidates for the board, overseeing board performance evaluations, and developing nomination guidelines in line with applicable laws and regulations. The committee is composed of a majority of independent non-executive directors and meets at least annually to fulfill its duties, ensuring a structured and transparent process for board nominations and governance.
HBM Holdings Ltd. has entered a strategic collaboration with Otsuka Pharmaceutical Co., Ltd. to advance the development and commercialization of HBM7020, a BCMAxCD3 bispecific T-cell engager for autoimmune diseases. This agreement grants Otsuka an exclusive license for global rights, excluding Greater China, and includes potential payments to HBM Holdings of up to $670 million, as well as tiered royalties on future sales. This partnership is expected to enhance HBM’s positioning in the T-cell engager market and may lead to further collaborations.
HBM Holdings Ltd. announced significant progress in its share repurchase program, having repurchased HK$130 million worth of shares in 2025, reflecting its commitment to enhancing shareholder value. The company has also entered into multiple strategic collaborations, including a major partnership with AstraZeneca, which could yield up to US$4.4 billion in milestone payments, underscoring its strong market positioning and potential for growth.
HBM Holdings Ltd. announced that the China National Intellectual Property Administration upheld its patent for a method of producing fully human heavy chain-only antibodies, following a challenge by Biocytogen Pharmaceuticals. This decision reinforces HBM’s intellectual property rights, allowing the company to continue leveraging its patented technology to develop innovative therapies, which could have significant implications for its market positioning and stakeholders.
HBM Holdings Ltd. announced that its subsidiary, Nona Biosciences, has entered into a license agreement with Visterra, Inc. to advance biotherapeutic treatments for immune-mediated and autoimmune diseases. This collaboration leverages Nona Biosciences’ HCAb Harbour Mice® technology, which is recognized for its reduced immunogenicity and versatility, potentially enhancing HBM Holdings’ market position in the biotechnology sector.
HBM Holdings Limited, incorporated in the Cayman Islands, announced the successful passage of all proposed resolutions during its Annual General Meeting held on June 11, 2025. Key resolutions included the adoption of financial statements, re-election of directors, auditor reappointment, and granting mandates for share issuance and repurchase. The AGM results reflect strong shareholder support for the company’s strategic decisions, potentially impacting its future operational and financial strategies.
HBM Holdings Limited has announced the appointment of Dr. Ian Yi Liu as a joint company secretary, effective June 9, 2025. Dr. Liu, who joined the company in March 2025 as a Senior Vice President and Global Head of Legal, brings extensive legal expertise and industry experience, having previously served as company secretary for Breas Medical Holdings AB and advised Shanghai Fosun Pharmaceutical. This strategic appointment is expected to enhance the company’s corporate governance and operational efficiency.
HBM Holdings Limited has announced a change in its company secretary position. Ms. Yifan Gao will cease to be a joint company secretary due to a change in her work arrangements, effective May 26, 2025. She has confirmed no disagreements with the board. Mr. Wing Yat Christopher Lui will continue as the sole company secretary, possessing the necessary qualifications and experience. The board expressed gratitude for Ms. Gao’s contributions during her tenure.
HBM Holdings Ltd. has announced that its first-in-human Phase 1 clinical study design for MesoC2, a mesothelin-targeting ADC, will be presented at the 2025 ASCO Annual Meeting by its collaborator, Pfizer. MesoC2, developed using HBM’s proprietary platforms, is being tested for safety and efficacy in patients with advanced solid tumors, potentially positioning it as a globally best-in-class therapeutic option.